Recently, INGIA, a Chinese synthetic biotech startup, announced the completion of tens of millions of yuan of round A financing. This round of financing will be used to accelerate the layout of the company in the field of synthetic biology.

Founded in 2015, INGIA is mainly engaged in the R&D, production, and sales of natural active ingredients and plant extracts. Its main products include stevioside, siraitin, alodonose, ferulic acid, vanillin, etc. which are widely used in the food and beverage, nutrition, and health products industries. The company is one of the few companies in the world to produce stevioside (sweetener) by biological method and has a leading R&D and production platform of synthetic biology.

Plant natural active ingredients have always been an important functional source of food, drugs, health products, and daily cosmetics. With the increasing demand for natural and nutritional products, natural active ingredients are increasingly widely used in the great health industry.

Taking sweeteners as an example, the main function of sweeteners is to replace sucrose, glucose, etc. The new stevioside products RD and RM produced by INGIA conform to the healthy concept of natural low-calorie sweetener, with good taste and broad application prospects. However, due to the limited supply of raw materials, natural content, and cost factors, the products from natural plant extraction have not fully met the market demand so far. INGIA continues to reduce costs through synthetic biology and is expected to significantly expand the applications of the product market in the future.